资讯

Swedish Orphan Biovitrum AB: FDA Accepts Biologics License Application for Sobi's NASP for ...

Submission includes results of the pivotal DISSOLVE I and II studiesNASP PDUFA date set for 27 June 2026STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical ...